GRAL
GRAIL, Inc. Common StockGRAL
GRAL
About: GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Employees: 1,000
0
Funds holding %
of 7,429 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
139% more call options, than puts
Call options by funds: $56.4M | Put options by funds: $23.6M
118% more capital invested
Capital invested by funds: $613M [Q1] → $1.34B (+$723M) [Q2]
83% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 40
31% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 74
8% more funds holding
Funds holding: 309 [Q1] → 335 (+26) [Q2]
1.59% more ownership
Funds ownership: 70.78% [Q1] → 72.37% (+1.59%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for GRAL.
Financial journalist opinion
Based on 4 articles about GRAL published over the past 30 days
Neutral
Seeking Alpha
1 week ago
GRAIL, Inc. (GRAL) Q2 2025 Earnings Call Transcript
GRAIL, Inc. (NASDAQ:GRAL ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Aaron Freidin - Chief Financial Officer Andrew John Partridge - Chief Commercial Officer Harpal S. Kumar - President of International Business & BioPharma Joshua J.
Neutral
PRNewsWire
1 week ago
GRAIL Reports Second Quarter 2025 Financial Results
Q2 U.S. Galleri Revenue Grew 21% Year-Over-Year to $34.2 Million Q2 Galleri Tests Sold Grew 29% Year-Over-Year to More Than 45,000 Detailed Results From First 25,000 Enrolled in PATHFINDER 2 to be Submitted for Presentation at ESMO 2025 in October MENLO PARK, Calif. , Aug. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the second quarter 2025.
Neutral
PRNewsWire
3 weeks ago
GRAIL to Present at Canaccord Genuity 45th Annual Growth Conference
MENLO PARK, Calif. , July 30, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on Wednesday, Aug. 13 at 8:30 a.m.
Neutral
PRNewsWire
3 weeks ago
GRAIL to Announce Second Quarter 2025 Financial Results
MENLO PARK, Calif. , July 29, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the second quarter 2025 following the close of market on Tuesday, Aug. 12, 2025.
Positive
WSJ
2 months ago
The Holy Grail of Automation: Now a Robot Can Unload a Truck
Technology breakthroughs are allowing DHL and other companies to automate the laborious, injury-prone work of loading and unloading.
Positive
Market Watch
2 months ago
Grail Shares Jump on Promising Results for Galleri Study
Shares of Grail climbed after the company said the second study of its Galleri multi-cancer early detection test provided even more promising results than the first.
Neutral
PRNewsWire
2 months ago
GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study
Cancer Detection and Positive Predictive Value Substantially Higher Than the Previously Published PATHFINDER Study MENLO PARK, Calif. , June 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced positive top-line performance and safety results from the pre-specified analysis of the first 25,578 participants in GRAIL's registrational PATHFINDER 2 study.
Neutral
Schaeffers Research
2 months ago
These 24 Stocks Are Ripe for a Short Squeeze
With the way negative stock market sentiment has piled up recently, short squeezes have generated some massive returns.
Positive
MarketBeat
2 months ago
3 Medical Technology Stocks Outperforming in 2025
As the broader market stages a sharp rebound from its April lows, several sectors, industries, and stocks have quietly emerged as leaders. Among them, the medical technology industry, known for its innovation and growth potential, has stood out.
Neutral
PRNewsWire
2 months ago
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif. , May 30, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 77,350 shares of GRAIL's common stock to 38 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.
Charts implemented using Lightweight Charts™